The Center for Clinical Trials | Saraland, AL

Research site

(Unclaimed)

Location

1008 Shelton Beach Road, Saraland, Alabama, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

Linaclotide

Iron

Centanafadine

SAR443765

Tenapanor

Lunsekimig

Obicetrapib

Loperamide

CIN-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 15 total trials

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess th...

Enrolling

Chronic Idiopathic Constipation (CIC)

Drug: Tenapanor 50 mg BID

Drug: Tenapanor 5 mg BID

Locations recently updated

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopa...

Active, not recruiting

Idiopathic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 15mg

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at differe...

Active, not recruiting

Hypertension

Drug: QCZ484

Other: Saline

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling

Attention-Deficit/Hyperactivity Disorder

Drug: Placebo

Drug: 100mg SPN-812

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (AIRLYMPUS)

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.The purpose of this study is...

Enrolling

Asthma

Drug: Budesonide/Albuterol

Drug: Lunsekimig